Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selexipag in Raynaud's Phenomenon Secondary to Systemic Sclerosis
NCT02260557Phase 2Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Oct 2014
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in Raynaud's phenomenon (RP) comparing Selexipag with Placebo (2 arms). Primary endpoint: Average number of Raynaud's phenomenon (RP) attacks per week. Started Oct 2014; status: completed.
02
Drugs
selexipag
03
Conditions
Raynaud's phenomenon (RP)
Beyond the preview
Go deeper on NCT02260557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02260557.